The Senate blue ribbon committee’s timeline on the Dengvaxia deal

The Senate blue ribbon committee currently holding a hearing on the controversial anti-dengue vaccine Dengvaxia on Monday released a timeline detailing the procurement of the vaccine and the implementation of the Department of Health's vaccination program.

TIMELINE OF DENGUE VACCINE PROCUREMENT AND VACCINATION IMPLEMENTATION PRESENTED BY SENATOR RICHARD GORDON by GMA News Online on Scribd

The DOH launched its immunization program in April 2016, and some 800,000 public school students  received doses of the vaccine, which is administered in three shots, each six months apart.

On November 29, pharmaceutical company Sanofi Pasteur, which manufactures the vaccine, announced that while Dengvaxia "provides persistent protective benefit" against dengue in people who had prior infection, severe forms of the disease could occur following vaccination in those not previously infected by the dengue virus.

The DOH stopped its immunization program on December 1, and the Food and Drug Administration suspended sales of the vaccine on December 4. — BM, GMA News